Regardless of the histologic tumor type and p16 expression status, cervical carcinomas show high Trop2 expression and, therefore, Trop2 directed ADCs such as Sacituzumab-Govitecan may represent a promising therapeutic target in this cancer type, including the prognostically poor HPV-independent (p16 negative) tumors, which occur much more frequently in the subgroup of cervical adenocarcinomas than in squamous cell carcinomas. The gene discussed is TACSTD2; the disease is cervical carcinoma.